![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1559497
¼¼°è Á¶Á÷ Áø´Ü »ê¾÷ÀÇ ¼ºÀå ±âȸ(2024-2029³â)Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024-2029 |
µ¿¹ÝÁø´ÜÀ» Àü¹®À¸·Î ´Ù·ç´Â ÷´Ü ¿°»ö°ú ¸ÖƼ¿À¹Í½º ±â´ÉÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø
¼¼°è Á¶Á÷ Áø´Ü ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á¿¡¼ Á¤È®ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°À» À§ÇÑ °í±Þ ¿°»öÀÇ Çʿ伺, Á¶Á÷ »ý°ËÀÇ °Ë»ç·®, »çÀü ºÐ¼® ¹× °í±Þ ¿°»ö Ç÷§ÆûÀÇ °³¹ß·Î ÀÎÇØ Å« ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2040³â±îÁö Àü ¼¼°è¿¡¼ ¾Ï ȯÀÚ°¡ 60% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â Á¶Á÷ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â Áø´Ü ÅøÀÇ °³¼±ÀÌ ¾ó¸¶³ª ½Ã±ÞÇÑÁö¸¦ Àß º¸¿©ÁÝ´Ï´Ù. ¾Ï Ä¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Á¶Á÷ Áø´ÜÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°è ½ÇÇè½ÇÀÇ ±â¼ú ¹× ¿ª·® Çâ»ó¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼ ¿¹»óµÇ´Â ¾Ï ¹ßº´·ü Áõ°¡¸¦ °ü¸®Çϱâ À§Çؼ´Â Áö¿ª³» Áø´Ü ´É·ÂÀ» Çâ»ó½ÃŰ´Â °ÍÀÌ ÇʼöÀûÀ̸ç, ÀÌ´Â °Ë»ç ¼Ò¿ä ½Ã°£°ú Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ãų ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.
Á¶Á÷ Áø´Ü »ê¾÷ÀÇ »çÀü ºÐ¼® ¿°»ö ½ÃÀåÀº ¿°»ö ±â¼úÀÇ ¹ßÀü, Â÷¼¼´ë ½ÃÄö½ÌÀ» °£¼ÒÈÇÏ´Â »çÀü ºÐ¼® Ç÷§Æû, ÀÚµ¿È ¿°»ö Ç÷§Æû, È¿À²¼º°ú ÀçÇö¼ºÀ» ÃËÁøÇÏ´Â °í󸮷® ½Ã½ºÅÛ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¶Á÷ Áø´Ü ¾÷üµéÀº Á¶Á÷ Áø´ÜÀÇ Æ¯À̼º°ú ¹Î°¨µµ¸¦ ³ôÀÌ´Â Çõ½ÅÀûÀ̰í Áøº¸µÈ ½Ã½ºÅÛ ¹× ¿°»ö °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ƯÈ÷ ISH ¹× IHC¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, º´¸® °Ë»çÀÇ ÀϺο¡ CDx¸¦ Æ÷ÇÔÇϵµ·Ï Àǹ«ÈµÇ´Â ±ÔÁ¦, ¹ÙÀÌ¿À Á¦¾à ȸ»ç¿Í Áø´Ü ÀǾàǰ ȸ»ç¿ÍÀÇ Á¦ÈÞ Áõ°¡ µîÀÌ ±× ¹è°æÀÔ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Ï Áø´Ü ÀÎÇÁ¶ó ¼ºÀå, ¾Ï ¹ßº´·ü Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, ÷´Ü Áø´Ü ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼º Áõ°¡, Á¤ºÎ Áö¿ø È®´ë µîÀº ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ½ÃÀåÀ¸·Î ºÎ»óÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
Companion Diagnostics-specific Advanced Staining and Multiomics Capabilities are Driving Market Growth
The global tissue diagnostics market will experience significant growth driven by the need for advanced staining in precise biomarker identification in personalized medicine, tissue biopsy test volumes, and pre-analytical and advanced staining platform development.
According to the WHO, there will be a 60% rise in cancer cases worldwide by 2040, which will fuel demand for tissue diagnostics. This increase highlights how urgently improved diagnostic tools are needed. The complexity of tissue diagnostics expanded due to advancements in cancer treatment, which require enhanced technology and capabilities in laboratories across the globe. Improving local diagnostic capacity is vital for managing the projected growth in cancer incidence worldwide, as it can improve test turnaround times and diagnostic accuracy-both of which substantially impact cancer treatment outcomes.
The pre-analytical staining market in the tissue diagnostics industry is being propelled by several key factors, such as growing advancements in staining technologies, pre-analytical platforms to simplify next-generation sequencing, automated staining platforms, and high-throughput systems to drive efficiency and reproducibility. Tissue diagnostics players are increasingly focusing on developing innovative and advanced systems and stains that enhance the specificity and sensitivity of tissue diagnostics. The advanced staining segment is the second leading segment due to a surge in adoption, especially driven by increased demand for ISH and IHC offerings, regulatory mandates to include CDx as part of pathology tests, and increased partnerships between biopharma companies and diagnostic companies.
Asia-Pacific's growing cancer diagnostics infrastructure, increasing cancer prevalence rate, rising healthcare spending, increasing access to advanced diagnostic technologies, and growing government support all contribute to the region being the fastest-growing market.